(0.32%) 5 116.46 points
(0.31%) 38 357 points
(0.36%) 15 984 points
(-0.89%) $83.10
(5.93%) $2.04
(0.36%) $2 355.70
(0.46%) $27.66
(3.94%) $958.45
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States...
Stats | |
---|---|
本日の出来高 | 300 576 |
平均出来高 | 624 422 |
時価総額 | 39.92M |
EPS | $0 ( 2024-03-04 ) |
次の収益日 | ( $-0.380 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.330 |
ATR14 | $0.00800 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Goncalves Joana | Sell | 2 753 | Common Stock |
2024-04-05 | Terrillion Scott | Sell | 2 753 | Common Stock |
2024-02-29 | Terrillion Scott | Sell | 3 293 | Common Stock |
2024-02-29 | Posner Christopher | Sell | 5 834 | Common Stock |
2024-02-29 | Goncalves Joana | Sell | 3 293 | Common Stock |
INSIDER POWER |
---|
72.30 |
Last 96 transactions |
Buy: 1 992 546 | Sell: 375 720 |
ボリューム 相関
Cara Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
CPTA | -0.959 |
XLRN | -0.958 |
FLMN | -0.955 |
ZGNX | -0.953 |
TIG | -0.952 |
ITI | -0.948 |
PPYAU | -0.948 |
RAM | -0.946 |
GPACU | -0.942 |
KTCC | -0.941 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cara Therapeutics Inc 相関 - 通貨/商品
Cara Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $20.97M |
総利益: | $14.54M (69.32 %) |
EPS: | $-2.19 |
FY | 2023 |
収益: | $20.97M |
総利益: | $14.54M (69.32 %) |
EPS: | $-2.19 |
FY | 2022 |
収益: | $41.87M |
総利益: | $34.60M (82.65 %) |
EPS: | $-1.550 |
FY | 2021 |
収益: | $23.03M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.740 |
Financial Reports:
No articles found.
Cara Therapeutics Inc
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。